Literature DB >> 16473279

X chromosomal abnormalities in basal-like human breast cancer.

Andrea L Richardson1, Zhigang C Wang, Arcangela De Nicolo, Xin Lu, Myles Brown, Alexander Miron, Xiaodong Liao, J Dirk Iglehart, David M Livingston, Shridar Ganesan.   

Abstract

Sporadic basal-like cancers (BLC) are a distinct class of human breast cancers that are phenotypically similar to BRCA1-associated cancers. Like BRCA1-deficient tumors, most BLC lack markers of a normal inactive X chromosome (Xi). Duplication of the active X chromosome and loss of Xi characterized almost half of BLC cases tested. Others contained biparental but nonheterochromatinized X chromosomes or gains of X chromosomal DNA. These abnormalities did not lead to a global increase in X chromosome transcription but were associated with overexpression of a small subset of X chromosomal genes. Other, equally aneuploid, but non-BLC rarely displayed these X chromosome abnormalities. These results suggest that X chromosome abnormalities contribute to the pathogenesis of BLC, both inherited and sporadic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473279     DOI: 10.1016/j.ccr.2006.01.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  410 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

3.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

4.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

5.  X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Authors:  Yang Liu; Lizhong Wang; Pan Zheng
Journal:  Trends Genet       Date:  2010-04-29       Impact factor: 11.639

6.  Systematic discovery of nonobvious human disease models through orthologous phenotypes.

Authors:  Kriston L McGary; Tae Joo Park; John O Woods; Hye Ji Cha; John B Wallingford; Edward M Marcotte
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

7.  Role of DeltaNp63gamma in epithelial to mesenchymal transition.

Authors:  Jaime Lindsay; Simon S McDade; Adam Pickard; Karen D McCloskey; Dennis J McCance
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

Review 8.  Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery.

Authors:  Dawn M Carone; Jeanne B Lawrence
Journal:  Semin Cancer Biol       Date:  2012-06-18       Impact factor: 15.707

9.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

10.  Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation.

Authors:  Wayne O Miles; Antonio Lembo; Angela Volorio; Elena Brachtel; Bin Tian; Dennis Sgroi; Paolo Provero; Nicholas Dyson
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.